Skip to content

S-ketamin Premedication in Pediatric EENT Surgery

A Comparison of S-ketamin, Dexmedetomidine, and Combination as Premedication in Children Undergoing ENT Surgery

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04757675
Enrollment
320
Registered
2021-02-17
Start date
2021-03-01
Completion date
2022-01-01
Last updated
2022-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emotions, Pain, Procedural, Separation Anxiety

Brief summary

We aim to investigate the effects of premedication (intranasal or intravenous administration) of s-ketamin, dexmedetomidine, and combination for premedication in children undergoing ENT surgery.

Detailed description

Three hundred children aged between 2 and 12 years were randomly allocated to one of five groups: 0.3 μg/kg intravenous injection s-ketamin; 0.5 μg/kg intravenous injection s-ketamin; 2 μg/kg intranasal s-ketamin group; 1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine group; 0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine group. The modified Yale Preoperative Anxiety Scale (m-YPAS) was used to assess preoperative anxiety at 1, 5, 10, 20, and 30min after premedication. A 4-point emotional state score was used to evaluate participators when they were separated from their parents and their response to intravenous cannulation or facemask application. Agitation scores (Pediatric Anesthesia Emergence Delirium \[PAED\] scale) and POV was assessed in the postanesthetic care unit (PACU). Times to endotracheal tube or laryngeal mask airway removal, discharge from the PACU, and patients' satisfaction degree were also assessed.

Interventions

DRUGS-ketamine 0.3

0.3 μg/kg intravenous injection s-ketamin

0.5 μg/kg intravenous injection s-ketamin

DRUGS-ketamine 2

2 μg/kg intranasal s-ketamin

DRUGS-ketamine 1+Dexmedetomidine 1

1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine

DRUGS-ketamine 0.5 +Dexmedetomidine 2

0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine

Sponsors

Eye & ENT Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* After obtaining the informed consent from their parents or proxies, the children aged 2 to 12 years, scheduled for elective ENT surgery, of American Society of Anesthesiologists (ASA) I or II were enrolled in this study.

Exclusion criteria

* Congenital heart diseases, congenital dysplasia, obstructive sleep apnea syndrome, upper respiratory tract infection, body mass index (BMI) ≥25, allergy to S-ketamin or dexmedetomidine, and severe liver or kidney disease.

Design outcomes

Primary

MeasureTime frameDescription
The modified Yale Preoperative Anxiety Scale1 min after premedicationA validated observational tool for assessing children's anxiety

Secondary

MeasureTime frameDescription
Parental Separation Anxiety Scale (PSAS)30 min after premedication1. = easy separation 2. = whimpers, but is easily reassured, not clinging 3. = cries and cannot be easily reassured, but not clinging to parents 4. = crying and clinging to parents
Emotional State Scale15 min after premedicationSuccessful venous cannulation was defined as an ESS-4 ≤2 at the time of attempted cannulation, regardless of whether the vein was actually cannulated on the first attempt.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026